POT-4 for Treatment of AMD

  • September 29, 2008

    POT-4 for Treatment of AMD

    by Dan Roberts (Updated September 29, 2008) Potentia Pharmaceuticals, Inc. announced on March 20, 2007 that it was entering the clinical phase of development of POT-4 for treatment of age-related macular degeneration (AMD). According to the researchers, POT-4, a synthetic peptide, shuts down the complement activation system that can lead to local inflammation, tissue damage […]